EUCTR2011-001237-16-NL进行中（未招募）不适用
High-dose alkylating chemotherapy in oligo-metastatic breast cancer harboring homologous recombination deficiency - OLIGO study
KI-AV0 个研究点开始时间: 2011年5月11日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1.Histologically or cytologically confirmed infiltrating breast cancer
- •2.Oligometastatic disease defined as one to three distant metastatic lesions, with or without primary tumor, local recurrence, or locoregional lymph node metastases, including the axillary, parasternal, and ipsilateral periclavicular regions. All lesions must be amenable to resection or radiotherapy with curative intent. Staging examinations must have included a PET-scan plus diagnostic CT-scan of the chest and abdomen, and an isotope bone scan. When the isotope bone scan is doubtful and plain radiographs do not explain the abnormality, MRI or CT-scan of the affected skeletal region must be performed.
- •3.The tumor must be HER2/neu-negative (either score 0 or 1 at immunohistochemistry or negative at in situ hybridization [CISH or FISH] in case of score 2 or 3 at immunohistochemistry).
- •4.The tumor must be ER and PgR negative (<10% nuclear staining at IHC) unless the patient is a known BRCA1 or BRCA2 mutation carrier. The rare tumors that are ER-negative and PgR-positive will be eligible, if this pattern of hormone receptor expression can be verified in the NKI-AVL reference pathology lab.
- •5.Age =18 years
- •6.World Health Organisation (WHO) performance status 0 or 1
- •7.Adequate bone marrow function (ANC =1.0 x 109/l, platelets =100 x 109/l)
- •8.Adequate hepatic function (ALAT, ASAT and bilirubin =2.5 times upper limit of normal)
- •9.Adequate renal function (creatinine clearance =60 ml/min)
- •10.LVEF =50% measured by echocardiography or MUGA
- •11.Absence of any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
- •12.Signed written informed consent
- •13.Able to comply with the protocol
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 100
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.No malignancy other than breast cancer, unless treated with curative intent without the use of chemotherapy or radiation therapy
- •2.No current pregnancy or breastfeeding. Women of childbearing potential must use adequate contraceptive protection.
- •3.No concurrent anti-cancer treatment or investigational drugs
研究者
相似试验
撤回
2 期
High-dose alkylating chemotherapy in oligo-metastatic breast cancer harboring homologous recombination deficiencymammary neoplasms10006291breast cancerNL-OMON36155ederlands Kanker Instituut100
进行中（未招募）
1 期
Study on intensive chemotherapy in patients with breast cancer with 1 to 3 metastatic lesions. The breast tumor has to harbor homologous recombination deficiencyOligo metastatic breast cancer harboring homologous recombination deficiency and/or the patient has a deleterious germline BRCA1 or BRCA2 mutationMedDRA version: 20.1 Level: PT Classification code 10055113 Term: Breast cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-000838-19-NLKI-AV74
招募中
3 期
High-dose alkylating chemotherapy in oligo-metastatic breast cancer harboring homologous recombination deficiencymammary neoplasms10006291breast cancerNL-OMON50592ederlands Kanker Instituut74
进行中（未招募）
3 期
High Dose Chemotherapy in Oligo-metastatic Homologous Recombination Deficient Breast CancerBreast CancerNCT01646034The Netherlands Cancer Institute74
进行中（未招募）
1 期
Transplantation of stem cells for the treatment of svere systemic sclerosis with a protocol which is adapted to individual manifestatons of the diseaseSystemic sclerosisEUCTR2011-002434-40-DEniversity Hospital Tuebingen44